|
The biopharmaceutical industry is in turmoil caused by patent cliffs, increasing regulatory and pricing risks, and the poor return on research investments. For decades, biotech startups have been the salvation; companies like Genentech have provided the necessary innovation. But many of the strategies used to build important companies in the 90's are no longer relevant. The need for new therapeutics and positive returns for investors has never been higher. Meeting this need is the challenge that Karl Handelsman (a venture capitalist with CMEA) is taking on. Karl has led the way on spinning out exciting new drug discovery platform companies, including Tetraphase and Intellikine. Join us for a dialogue on what it takes to succeed in today's environment.
Lunch provided, but space is limited so please reserve a seat at http://www.acteva.com/booking.cfm?bevaid=189194
|
 Karl Handelsman, Managing Director, CMEA Capital
Karl Handelsman joined CMEA Capital in 1999 and has been involved with numerous CMEA investments such as: Ambrx, Ensemble Discovery, Ilypsa, Intellikine, Kalypsys, Maxygen, Phenomix, Rigel, Syrrx, Tetraphase, and Xenoport. Prior to joining CMEA, Karl was one of the first employees of Tularik, Inc., a drug discovery company, where his business development role spanned corporate partnering, technology licensing, and operations. Karl was also one of the first employees of Whitehead Institute, a premier research organization within Massachusetts Institute of Technology (MIT); and he worked in business development at Millennium Pharmaceuticals. Karl holds graduate degrees from both MIT and Harvard Medical School.
|
